Leading regenerative medicine company focusing on developing, manufacturing, and commercialization of placental derived tissue allografts, BioStem Technologies Inc (OTCMKTS:BSEM), on September 8, 2022, announced the appointment of Brandon Poe as Independent Board Member as well as Chair of the Audit Committee.
Trading Data
On Thursday, BSEM stock decreased 0.66% to $2.2700 with more than 300 shares, compared to its average volume of 3.10K shares. The stock moved within a range of $2.2700 – 2.2700 after opening trade at $2.2700.
BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe
Jason Matuszewski, Chief Executive Officer of BioStem Technologies said that the company is delighted on welcoming Brandon Poe to the Board of Directors. The CEO added that Brandon brings extensive leadership experience in the biotech sector. Furthermore, the CEO said that Poe has precious insights into expanding the regulatory and financial framework.
Matuszewski also said that the firm is looking to Poe’s expertise in raising capital, establishing robust internal controls as well as preparing financial reports.
An experienced executive with over two and half decades of financial experience across different industries, Poe currently serves as Chief Financial Officer of Jumpcode Genomics, a genomic tools company. He had earlier been the CFO at Genome Medical, a genomic telehealth provider. Poe also was the Vice President of Finance at Illumina; CFO at Sotera Wireless and Vice President of Finance at Inverness Medical Innovations.
Poe expressed excitement about serving the Board of Directors, which continues to outperform other regenerative medicine companies.
Andrew Van Vurst, Chief Operating Officer of BioStem Technologies said that the company continues to strengthen the Board of Directors with experts.
Key Quote
“I am excited to serve on the Board of Directors of an innovative company that continues to outperform other regenerative medicine companies in its field. I look forward to advising the Company on the optimal methods to expand the access of its perinatal-derived tissue allografts for advanced wound care,” said Mr. Poe.
Technical Data
BSEM stock is trading below the 20-Day and 50-Day Moving averages of $2.73 and $2.37 respectively. However, the stock is trading above the 200-Day moving average of $1.52. The company has a total market capitalization of $21 million.
